Maribavir effectively treated three patients with human herpesvirus-6B infection after allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.cn121090-20250206-00054
- VernacularTitle:马立巴韦治疗3例异基因造血干细胞移植后HHV-6B感染的疗效及安全性
- Author:
Chengwei JIN
1
;
Su LI
;
Luxiang WANG
;
Jiayu HUANG
;
Xiaoxia HU
;
Zilu ZHANG
Author Information
1. 上海交通大学医学院附属瑞金医院血液科，上海血液学研究所，国家转化医学研究中心，上海 200025
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(7):663-665
- CountryChina
- Language:Chinese
-
Abstract:
Human herpesvirus-6B (HHV-6B) reactivation is a significant contributor to nonrelapse mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). This retrospective analysis describes three cases of HHV-6B reactivation following allo-HSCT, all of which achieved viral clearance with maribavir treatment following failure or intolerance to first-line antiviral therapy with foscarnet sodium. One patient diagnosed with HHV-6B encephalitis recovered without neurological sequelae. No adverse drug reactions to maribavir were observed. These findings provide preliminary evidence that maribavir may serve as an effective and safe salvage therapy for HHV-6B reactivation in patients receiving allo-HSCT.
